Literature DB >> 11941228

Post-ECT Delirium.

Max Fink1.   

Abstract

A confusional state accompanied by restlessness is a frequent occurrence at the end of an induced seizure in electroconvulsive therapy (ECT). Delirium, which usually lasts <1 h, occurs in up to 12% of patients. It is most frequent during the initial treatments of a series. The occurrence of delirium in one treatment is not a harbinger of its reappearance in later treatments. Usually gentle reassurance is sufficient to help the patient, but some instances warrant the administration of diazepam, midazolam, a barbiturate, or droperidol.

Entities:  

Year:  1993        PMID: 11941228

Source DB:  PubMed          Journal:  Convuls Ther        ISSN: 0749-8055


  10 in total

1.  The Role of Acetylcholinesterase Inhibitors in the Treatment of Prolonged Postelectroconvulsive Therapy Delirium.

Authors:  Brianna Gutowski; Emily Bomasang-Layno
Journal:  Case Rep Psychiatry       Date:  2022-05-30

2.  Premedication with dexmedetomidine and midazolam attenuates agitation after electroconvulsive therapy.

Authors:  Ayse Mizrak; Senem Koruk; Suleyman Ganidagli; Mahmut Bulut; Unsal Oner
Journal:  J Anesth       Date:  2009-02-22       Impact factor: 2.078

3.  Delayed Onset and Prolonged ECT-Related Delirium.

Authors:  Sameer Hassamal; Ananda Pandurangi; Vasu Venkatachalam; James Levenson
Journal:  Case Rep Psychiatry       Date:  2013-09-03

4.  Ketofol-Dexmedetomidine combination in ECT: A punch for depression and agitation.

Authors:  Tarek Shams; Ragaa El-Masry
Journal:  Indian J Anaesth       Date:  2014-05

5.  Prolonged Post-electroconvulsive Therapy Delirium: An Unusual Presentation.

Authors:  Ahmad R Khan; Hafsa Mahmood; Saad Wasiq; Hina Saeed
Journal:  Cureus       Date:  2018-08-28

6.  The incidence of prolonged post-electroconvulsive therapy delirium: A retrospective study.

Authors:  Sandeep Grover; Ajay Kumar; Subho Chakrabarti; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2020-03-17       Impact factor: 1.759

7.  Factors associated with post-electroconvulsive therapy delirium: A retrospective chart review study.

Authors:  Young Tak Jo; Sung Woo Joo; Jungsun Lee; Yeon Ho Joo
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

8.  A comparative study of propofol, thiopentone sodium, and ketofol as induction agents for electro convulsive therapy.

Authors:  Nagraju R Gaddam; Vasanti P Kelkar Sasturkar; Sanhita J Kulkarni; Pradnya S Joshi; Pramod V Bhale
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2022-01-06

9.  Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods.

Authors:  Marieke J Henstra; Thomas C Feenstra; Rob M Kok; Harm-Pieter Spaans; Eric van Exel; Annemiek Dols; Mardien Oudega; Anton C M Vergouwen; Adriano van der Loo; Pierre M Bet; Stephan A Loer; Merijn Eikelenboom; Pascal Sienaert; Simon Lambrichts; Filip Bouckaert; Judith E Bosmans; Nathalie van der Velde; Aartjan T F Beekman; Max L Stek; Didi Rhebergen
Journal:  Front Psychiatry       Date:  2022-07-15       Impact factor: 5.435

10.  Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol.

Authors:  Ben J A Palanca; Hannah R Maybrier; Angela M Mickle; Nuri B Farber; R Edward Hogan; Emma R Trammel; J Wylie Spencer; Donald D Bohnenkamp; Troy S Wildes; ShiNung Ching; Eric Lenze; Mathias Basner; Max B Kelz; Michael S Avidan
Journal:  Front Psychiatry       Date:  2018-05-14       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.